Prelude announces publication of abstracts on SMARCA Degrader Programs

Prelude Therapeutics announced the publication of three abstracts regarding its SMARCA Degrader Programs at the 36th EORTC-NCI-AACR Symposium taking place in Barcelona, Spain October 23-25, 2024. “We are delighted to have this opportunity to share additional information from our SMARCA degrader programs to the scientific and medical communities as we continue to progress both the clinical and preclinical development of these novel first-in-class approaches for patients with high unmet needs,” stated Kris Vaddi, CEO. “In addition to the updates we will be providing from our Phase 1 trial of PRT3789, we are looking forward to presenting the first preclinical data from our precision degrader antibody conjugates program. These data demonstrate that a highly potent dual SMARCA2/4 degrader payload can be conjugated to an antibody to specifically target tumor cells and safely induce tumor regressions in preclinical models. This approach has potential to replace chemotherapy payloads on ADCs and expand the therapeutic opportunities well beyond SMARCA4 mutated cancers.” PRT3789 is a potent and highly selective SMARCA2 degrader, in Phase 1 clinical development in biomarker selected SMARCA4 mutant patients. Enrollment remains on track, and the Company expects to conclude monotherapy dose escalation by year end 2024 and identify the biologically active dose to advance for future trials. In addition, enrollment of patients into back-fill cohorts enriched for NSCLC and SMARCA4 loss-of-function mutations and higher dose levels is ongoing. The objective is to assess clinical activity in a more homogeneous group of patients with high unmet need, at the biologically active dose, to support planned discussions with regulatory agencies.